Relmada Therapeutics (RLMD) Asset Utilization Ratio (2013)

Relmada Therapeutics' (RLMD) quarterly Asset Utilization Ratio came in at 0.3 in Q4 2013, down 27.88% on a QoQ basis from 0.41 in Q3 2013.

Relmada Therapeutics (RLMD) Asset Utilization Ratio (2013) Analysis & Trends

Relmada Therapeutics (RLMD) has 1 years of Asset Utilization Ratio data on file, last reported at 0.3 in Q4 2013.

On a quarterly basis, Asset Utilization Ratio changed N/A year-over-year to 0.3 in Q4 2013; TTM through Nov 2013 was 0.3, a N/A change from a year earlier, with the FY2013 full-year figure at 0.27, changed N/A from the prior year.
Asset Utilization Ratio for Q4 2013 stood at 0.3, down from 0.41 in the prior quarter.
Over the last five years, Asset Utilization Ratio for RLMD reached as high as 0.89 in Q2 2013 and fell as low as 0.3 in Q4 2013.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Asset Util. (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	0.69
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	0.47
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	0.37
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Relmada Therapeutics	205.29 Mn	205.29 Mn	-	-

Download Data